Header Logo

Connection

CHING-WEI DAVID TZENG to Male

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Male.
CHING-WEI DAVID TZENG
Connection Strength
1.083
Male
  1. Opioid-Free Discharge After Pancreatic Resection Through a Learning Health System Paradigm. JAMA Surg. 2023 Nov 01; 158(11):e234154.
    View in: PubMed
    Score: 0.029
  2. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol. 2022 Mar; 40:101673.
    View in: PubMed
    Score: 0.025
  3. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. J Surg Oncol. 2021 Dec; 124(8):1381-1389.
    View in: PubMed
    Score: 0.025
  4. Sustained reduction in discharge opioid volumes through provider education: Results of 1168 cancer surgery patients over 2 years. J Surg Oncol. 2021 Jul; 124(1):143-151.
    View in: PubMed
    Score: 0.024
  5. Assessing the 5?-Multiplier Calculation to Reduce Discharge Opioid Prescription Volumes After Inpatient Surgery. JAMA Surg. 2020 12 01; 155(12):1166-1167.
    View in: PubMed
    Score: 0.024
  6. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1563-1569.
    View in: PubMed
    Score: 0.023
  7. Clinical Factors Associated With Practice Variation in Discharge Opioid Prescriptions After Pancreatectomy. Ann Surg. 2020 07; 272(1):163-169.
    View in: PubMed
    Score: 0.023
  8. Early postoperative drain fluid amylase in risk-stratified patients promotes tailored post-pancreatectomy drain management and potential for accelerated discharge. Surgery. 2020 02; 167(2):442-447.
    View in: PubMed
    Score: 0.022
  9. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
    View in: PubMed
    Score: 0.021
  10. Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients. Ann Surg Oncol. 2019 Oct; 26(11):3428-3435.
    View in: PubMed
    Score: 0.021
  11. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res. 2019 11; 243:90-99.
    View in: PubMed
    Score: 0.021
  12. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. HPB (Oxford). 2019 09; 21(9):1203-1210.
    View in: PubMed
    Score: 0.021
  13. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB (Oxford). 2019 06; 21(6):662-668.
    View in: PubMed
    Score: 0.021
  14. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford). 2019 07; 21(7):841-848.
    View in: PubMed
    Score: 0.021
  15. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. J Surg Res. 2018 10; 230:148-154.
    View in: PubMed
    Score: 0.020
  16. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. J Surg Oncol. 2018 Jun; 117(8):1648-1654.
    View in: PubMed
    Score: 0.020
  17. Portal Vein Embolization Reduces Postoperative Hepatic Insufficiency Associated with Postchemotherapy Hepatic Atrophy. J Gastrointest Surg. 2018 01; 22(1):60-67.
    View in: PubMed
    Score: 0.019
  18. Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. J Surg Res. 2017 06 15; 214:229-239.
    View in: PubMed
    Score: 0.018
  19. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. J Surg Res. 2017 06 15; 214:1-8.
    View in: PubMed
    Score: 0.018
  20. Thromboelastography demonstrates perioperative hypercoagulability in hepato-pancreato-biliary patients and supports routine administration of preoperative and early postoperative venous thromboembolism chemoprophylaxis. HPB (Oxford). 2017 02; 19(2):154-161.
    View in: PubMed
    Score: 0.018
  21. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep; 114(4):451-5.
    View in: PubMed
    Score: 0.017
  22. Increased morbidity and mortality of a concomitant colectomy during a pancreaticoduodenectomy: an NSQIP propensity-score matched analysis. HPB (Oxford). 2015 Sep; 17(9):846-54.
    View in: PubMed
    Score: 0.016
  23. Identifying Esophagectomy Patients at Risk for Predischarge Versus Postdischarge Venous Thromboembolism. Ann Thorac Surg. 2015 Sep; 100(3):932-8; discussion 938.
    View in: PubMed
    Score: 0.016
  24. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg. 2015 Apr; 220(4):510-20.
    View in: PubMed
    Score: 0.016
  25. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.015
  26. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.014
  27. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.014
  28. Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients. HPB (Oxford). 2014 May; 16(5):459-68.
    View in: PubMed
    Score: 0.014
  29. Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients. HPB (Oxford). 2013 Oct; 15(10):773-80.
    View in: PubMed
    Score: 0.014
  30. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford). 2014 Apr; 16(4):373-83.
    View in: PubMed
    Score: 0.014
  31. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013 Feb; 20(2):482-90.
    View in: PubMed
    Score: 0.013
  32. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford). 2012 Aug; 14(8):506-13.
    View in: PubMed
    Score: 0.013
  33. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.013
  34. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology. 2010 May; 15(4):700-5.
    View in: PubMed
    Score: 0.011
  35. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res. 2007 Nov; 143(1):20-6.
    View in: PubMed
    Score: 0.010
  36. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol. 2007 Jul; 14(7):2150-8.
    View in: PubMed
    Score: 0.009
  37. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007 Apr; 141(4):464-9.
    View in: PubMed
    Score: 0.009
  38. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer. 2006 Jul 15; 107(2):371-9.
    View in: PubMed
    Score: 0.009
  39. Incidental Ring-hyperenhancing Liver Micronodules at CT Hepatic Arteriography-guided Percutaneous Thermal Ablation of Colorectal Liver Metastases. Radiol Imaging Cancer. 2024 Mar; 6(2):e230099.
    View in: PubMed
    Score: 0.007
  40. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
    View in: PubMed
    Score: 0.007
  41. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec; 24(12):1387-1398.
    View in: PubMed
    Score: 0.007
  42. Prophylactic Antibiotic Duration and Infectious Complications in Pancreatoduodenectomy Patients With Biliary Stents: Opportunity for De-escalation. Ann Surg. 2024 Apr 01; 279(4):657-664.
    View in: PubMed
    Score: 0.007
  43. Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study. Ann Surg Oncol. 2023 Aug; 30(8):4904-4911.
    View in: PubMed
    Score: 0.007
  44. Readmissions From Venous Thromboembolism After Complex Cancer Surgery. JAMA Surg. 2022 04 01; 157(4):312-320.
    View in: PubMed
    Score: 0.006
  45. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.006
  46. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729.
    View in: PubMed
    Score: 0.006
  47. Fast-track two-stage hepatectomy by concurrent portal vein embolization at first-stage hepatectomy in hybrid interventional radiology / operating suite. Surg Oncol. 2021 Dec; 39:101648.
    View in: PubMed
    Score: 0.006
  48. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.006
  49. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal?Cancer. J Am Coll Surg. 2021 08; 233(2):272-284.e13.
    View in: PubMed
    Score: 0.006
  50. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
    View in: PubMed
    Score: 0.006
  51. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.006
  52. Lymph node sampling in resectable hepatocellular carcinoma: national practice patterns and predictors of positive lymph nodes. Surg Oncol. 2021 Mar; 36:138-146.
    View in: PubMed
    Score: 0.006
  53. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.006
  54. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 2020 11; 5(6):e000960.
    View in: PubMed
    Score: 0.006
  55. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.006
  56. An Educational Intervention Reduces Opioids Prescribed Following General Surgery Procedures. J Surg Res. 2021 01; 257:399-405.
    View in: PubMed
    Score: 0.006
  57. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.006
  58. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.006
  59. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol. 2020 Oct; 27(10):3939-3947.
    View in: PubMed
    Score: 0.006
  60. Comprehensive Complication Index Validates Improved Outcomes Over Time Despite Increased Complexity in 3707 Consecutive Hepatectomies. Ann Surg. 2020 04; 271(4):724-731.
    View in: PubMed
    Score: 0.006
  61. Hepatic vein embolization after portal vein embolization to induce additional liver hypertrophy in patients with metastatic colorectal carcinoma. Eur Radiol. 2020 Jul; 30(7):3862-3868.
    View in: PubMed
    Score: 0.006
  62. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. J Phys Act Health. 2019 12 01; 16(12):1113-1122.
    View in: PubMed
    Score: 0.005
  63. Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma? HPB (Oxford). 2020 04; 22(4):545-552.
    View in: PubMed
    Score: 0.005
  64. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
    View in: PubMed
    Score: 0.005
  65. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin Cancer Res. 2019 10 01; 25(19):5843-5851.
    View in: PubMed
    Score: 0.005
  66. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. J Am Coll Surg. 2019 09; 229(3):286-294.e1.
    View in: PubMed
    Score: 0.005
  67. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Ann Surg. 2019 05; 269(5):917-923.
    View in: PubMed
    Score: 0.005
  68. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. J Gastrointest Surg. 2020 02; 24(2):368-379.
    View in: PubMed
    Score: 0.005
  69. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas. 2019 02; 48(2):216-222.
    View in: PubMed
    Score: 0.005
  70. Incidental versus non-incidental gallbladder cancer: index cholecystectomy before oncologic re-resection negatively impacts survival in T2b tumors. HPB (Oxford). 2019 08; 21(8):1046-1056.
    View in: PubMed
    Score: 0.005
  71. Positive cystic duct margin at index cholecystectomy in incidental gallbladder cancer is an important negative prognosticator. Eur J Surg Oncol. 2019 Jun; 45(6):1061-1068.
    View in: PubMed
    Score: 0.005
  72. Intrahepatic Recurrence Patterns Predict Survival After Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2019 Jan; 26(1):275-281.
    View in: PubMed
    Score: 0.005
  73. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.005
  74. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery. 2019 02; 165(2):329-336.
    View in: PubMed
    Score: 0.005
  75. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2019 07; 218(1):145-150.
    View in: PubMed
    Score: 0.005
  76. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
    View in: PubMed
    Score: 0.005
  77. Long-term survival after post-hepatectomy liver failure for colorectal liver metastases. HPB (Oxford). 2019 03; 21(3):361-369.
    View in: PubMed
    Score: 0.005
  78. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival. J Gastrointest Surg. 2019 01; 23(1):84-92.
    View in: PubMed
    Score: 0.005
  79. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730.
    View in: PubMed
    Score: 0.005
  80. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. Anticancer Res. 2018 Jul; 38(7):4035-4039.
    View in: PubMed
    Score: 0.005
  81. Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. Surgery. 2018 09; 164(3):424-431.
    View in: PubMed
    Score: 0.005
  82. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2018 Aug; 25(8):2457-2466.
    View in: PubMed
    Score: 0.005
  83. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715.
    View in: PubMed
    Score: 0.005
  84. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol. 2018 05; 44(5):684-692.
    View in: PubMed
    Score: 0.005
  85. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg. 2018 03; 267(3):552-560.
    View in: PubMed
    Score: 0.005
  86. Two-Stage Hepatectomy vs One-Stage Major Hepatectomy with Contralateral Resection or Ablation for Advanced Bilobar Colorectal Liver Metastases. J Am Coll Surg. 2018 05; 226(5):825-834.
    View in: PubMed
    Score: 0.005
  87. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.005
  88. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. J Gastrointest Surg. 2018 04; 22(4):703-712.
    View in: PubMed
    Score: 0.005
  89. Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis. Eur J Surg Oncol. 2018 01; 44(1):122-129.
    View in: PubMed
    Score: 0.005
  90. Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. Ann Surg Oncol. 2018 Jan; 25(1):107-116.
    View in: PubMed
    Score: 0.005
  91. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.005
  92. Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg. 2018 03; 22(3):467-476.
    View in: PubMed
    Score: 0.005
  93. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13):3954-3963.
    View in: PubMed
    Score: 0.005
  94. Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival. HPB (Oxford). 2018 01; 20(1):57-63.
    View in: PubMed
    Score: 0.005
  95. Operative and short-term oncologic outcomes of laparoscopic versus open liver resection for colorectal liver metastases located in the posterosuperior liver: a propensity score matching analysis. Surg Endosc. 2018 04; 32(4):1776-1786.
    View in: PubMed
    Score: 0.005
  96. Long term outcome after resection of liver metastases from squamous cell carcinoma. Eur J Surg Oncol. 2017 Nov; 43(11):2129-2134.
    View in: PubMed
    Score: 0.005
  97. Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. J Gastrointest Surg. 2018 01; 22(1):43-51.
    View in: PubMed
    Score: 0.005
  98. Tips and tricks of splenic vessel preservation during laparoscopic distal pancreatectomy. Surg Endosc. 2018 04; 32(4):2149-2150.
    View in: PubMed
    Score: 0.005
  99. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017 10; 162(4):752-765.
    View in: PubMed
    Score: 0.005
  100. Effective Laparoscopic Management Lymph Node Dissection for Gallbladder Cancer. Ann Surg Oncol. 2017 Jul; 24(7):1852.
    View in: PubMed
    Score: 0.005
  101. Borderline operability in hepatectomy patients is associated with higher rates of failure to rescue after severe complications. J Surg Oncol. 2017 Mar; 115(3):337-343.
    View in: PubMed
    Score: 0.004
  102. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma. Am J Surg. 2016 Aug; 212(2):238-45.
    View in: PubMed
    Score: 0.004
  103. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford). 2016 Jan; 18(1):29-34.
    View in: PubMed
    Score: 0.004
  104. Positive Impact of Epidural Analgesia on Oncologic Outcomes in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2016 Mar; 23(3):1003-11.
    View in: PubMed
    Score: 0.004
  105. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73.
    View in: PubMed
    Score: 0.004
  106. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.004
  107. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol. 2016; 55(3):265-77.
    View in: PubMed
    Score: 0.004
  108. Risk factors for 30-day readmissions after hepatectomy: analysis of 2444 patients from the ACS-NSQIP database. J Gastrointest Surg. 2015 Feb; 19(2):266-71.
    View in: PubMed
    Score: 0.004
  109. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
    View in: PubMed
    Score: 0.004
  110. The palliative index: predicting outcomes of emergent surgery in patients with cancer. J Palliat Med. 2014 Jan; 17(1):37-42.
    View in: PubMed
    Score: 0.004
  111. Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications. J Am Coll Surg. 2013 Dec; 217(6):1028-37.
    View in: PubMed
    Score: 0.004
  112. Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients. J Gastrointest Surg. 2014 Jan; 18(1):45-51.
    View in: PubMed
    Score: 0.004
  113. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 2014 Apr; 16(4):350-6.
    View in: PubMed
    Score: 0.004
  114. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013 Dec; 20(13):4073-9.
    View in: PubMed
    Score: 0.004
  115. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013 Aug; 20(8):2493-500.
    View in: PubMed
    Score: 0.003
  116. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. Ann Surg Oncol. 2012 Feb; 19(2):443-54.
    View in: PubMed
    Score: 0.003
  117. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res. 2009 Nov 15; 15(22):6963-72.
    View in: PubMed
    Score: 0.003
  118. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009 May; 18(5):1562-9.
    View in: PubMed
    Score: 0.003
  119. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clin Cancer Res. 2008 Oct 01; 14(19):6023-32.
    View in: PubMed
    Score: 0.003
  120. Radiofrequency ablation for unresectable tumors of the liver. Am Surg. 2008 Jul; 74(7):594-600; discussion 600-1.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.